Evidence map›Paper›PMID 41369745›Full record

ReviewPathologie (Heidelberg, Germany)2026

[Biomarker testing for carcinomas of the upper gastrointestinal tract].

Drolaiz H W Liu, Gudrun Piringer, Sabina Köfler, Rupert Langer

Abstract readReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Pathologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Drolaiz H W LiuKlinisches Institut für Pathologie und Molekularpathologie, Johannes Kepler Universität Linz und Kepler Universitätsklinikum GmbH, Krankenhausstr. 5-8, 4021, Linz, Österreich.
Gudrun PiringerDepartment of Pathology, GROW School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, Niederlande.
Sabina KöflerKlinisches Institut für Pathologie und Molekularpathologie, Johannes Kepler Universität Linz und Kepler Universitätsklinikum GmbH, Krankenhausstr. 5-8, 4021, Linz, Österreich.
Rupert LangerKlinisches Institut für Pathologie und Molekularpathologie, Johannes Kepler Universität Linz und Kepler Universitätsklinikum GmbH, Krankenhausstr. 5-8, 4021, Linz, Österreich. rupert.langer@kepleruniklinikum.at.ORCID http://orcid.org/0000-0001-9491-3609

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Predictive biomarker testing is nowadays an integral part of modern diagnostics and treatment planning for esophageal and gastric cancer. It currently consists mainly of immunohistochemically determined markers, namely the PD-L1 status (stated by the Tumor Proportion Score [TPS], Combined Positivity Score [CPS] and Tumor Area Proportion [TAP] Score) in esophageal squamous cell carcinomas, as well as the HER2 status (supplemented by in situ hybridization in case of equivocal results), the mismatch repair status (optionally supplemented by molecular pathological determination of microsatellite status), and, since mid-2024, the expression of claudin 18.2 in gastroesophageal adenocarcinomas. An expansion of the panel by FGFR2b is expected in the near future. In addition to the quality guideline-compliant technical performance of the tests, the biological heterogeneity of many of these biomarkers is also a diagnostic and clinical challenge. The current article provides an overview of current biomarker testing in the context of current treatment options for cancer of the upper gastrointestinal tract.

Indexed as

Biomarkers, TumorEsophageal NeoplasmsGastrointestinal NeoplasmsStomach NeoplasmsAdenocarcinomaB7-H1 AntigenCarcinoma, Squamous CellDNA Mismatch RepairErb-b2 Receptor Tyrosine KinasesHumansImmunohistochemistryB7-H1 AntigenBiomarkers, TumorCD274 protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesClaudin 18.2Esophageal cancerGastric cancerHER2Microsatellite instabilityPD-L1

Identifiers

PMID41369745
PMCPMC13109289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.